HTA – Go Job Zone

More evidence that there are diminishing marginal returns to quality of life gains – Healthcare Economist

February 25, 2025

0 Comments

More evidence that there are diminishing marginal returns to quality of life gains – Healthcare Economist

Quality-adjusted life years (QALYs) are commonly used to evaluate the impact of new medical technologies on patient mortality and ...

What is the PICOSI framework? – Healthcare Economist

January 6, 2025

0 Comments

What is the PICOSI framework? – Healthcare Economist

When conducting evidence synthesis, many individuals use the PICO framework. PICO stands for population; intervention; comparator(s); and outcome. This ...

Can we measure this? – Healthcare Economist

December 18, 2024

0 Comments

Can we measure this? – Healthcare Economist

A paper by Kowal et al. (2023) does in fact measure the disparities in health outcomes. To do this, they use data from the ...

Does NICE consider real-world data (RWD) for HTA evaluations? – Healthcare Economist

December 4, 2024

0 Comments

Does NICE consider real-world data (RWD) for HTA evaluations? – Healthcare Economist

The answer is ‘yes’, but the question is in what manner? A paper by Che et al. (2024) examines the use of real-world data ...

Should Dynamic Drug Pricing be Incorporated into Cost-Effectiveness Analyses? – Healthcare Economist

November 4, 2024

0 Comments

Should Dynamic Drug Pricing be Incorporated into Cost-Effectiveness Analyses? – Healthcare Economist

Cost effectiveness analyses (CEA) aim to examine how a new health technologies impact health outcomes and costs over a patient’s lifetime. While extrapolating long-run ...

What are the potential productivity impacts of new medications that treat Medicare beneficiaries? – Healthcare Economist

August 22, 2024

0 Comments

What are the potential productivity impacts of new medications that treat Medicare beneficiaries? – Healthcare Economist

One key aspect of many medications is that they not only help people feel better, but often these medications ...

Methods for Including Adverse Events in Economic Evaluations – Healthcare Economist

July 31, 2024

0 Comments

Methods for Including Adverse Events in Economic Evaluations – Healthcare Economist

That is the title of a great review paper by Salah Ghabri, Dalia Dawoud and Michael Drummond. They discuss that guidance on the incorporation ...

HTA and cell and gene therapy – Healthcare Economist

July 2, 2024

0 Comments

HTA and cell and gene therapy – Healthcare Economist

A paper by Drummond et al. (2023) examines how health technology assessment bodies deal with the challenge of value ...

Challenges in Conducting Economic Evaluations for Orphan Drugs in Rare Diseases – Healthcare Economist

June 5, 2024

0 Comments

Challenges in Conducting Economic Evaluations for Orphan Drugs in Rare Diseases – Healthcare Economist

Why is it so hard to estimate the value of orphan drugs indicated for the treatment of rare diseases? ...

Category: HTA

More evidence that there are diminishing marginal returns to quality of life gains – Healthcare Economist

What is the PICOSI framework? – Healthcare Economist

Can we measure this? – Healthcare Economist

Does NICE consider real-world data (RWD) for HTA evaluations? – Healthcare Economist

Should Dynamic Drug Pricing be Incorporated into Cost-Effectiveness Analyses? – Healthcare Economist

What are the potential productivity impacts of new medications that treat Medicare beneficiaries? – Healthcare Economist

Methods for Including Adverse Events in Economic Evaluations – Healthcare Economist

HTA and cell and gene therapy – Healthcare Economist

Challenges in Conducting Economic Evaluations for Orphan Drugs in Rare Diseases – Healthcare Economist

Call us

(469) 663-8558

For Candidates

Helpful Resources

About Us

Call us

(469) 663-8558

For Candidates

Helpful Resources

About Us

Ready to find your dream job?​

Ready to find your dream job?​

Ready to find your dream job?

Ready to find your dream job?